Can you prescribe a medication for chronic obstructive pulmonary disease (COPD)?

COPD Prescription Recommendation

For a patient with COPD, start with a short-acting bronchodilator (SABD) as needed for all patients, then escalate based on symptom burden and exacerbation risk: use LAMA/LABA dual therapy for moderate-to-high symptoms (CAT ≥10 or mMRC ≥2) with FEV₁ <80%, and add inhaled corticosteroid (ICS) for triple therapy only if the patient has ≥2 moderate or ≥1 severe exacerbations per year. 1

Algorithmic Approach to COPD Pharmacotherapy

Step 1: Universal Foundation

• All COPD patients should receive a short-acting bronchodilator (albuterol or ipratropium) for as-needed use, regardless of disease severity 1
• This accompanies all other therapies across the COPD spectrum

Step 2: Assess Symptom Burden and Lung Function

Low symptom burden (CAT <10, mMRC <2) AND FEV₁ ≥80%:

• Start with a single long-acting bronchodilator (LABA or LAMA) 1
• Options: tiotropium (LAMA), salmeterol, formoterol, indacaterol, or olodaterol (LABAs)

Moderate-to-high symptoms (CAT ≥10 or mMRC ≥2) AND FEV₁ <80%:

• LAMA/LABA dual therapy is the preferred initial maintenance treatment 1
• This combination is superior to ICS/LABA due to better lung function improvements and lower pneumonia risk 1
• Single-inhaler combinations are preferred for adherence

Step 3: Evaluate Exacerbation Risk

Low exacerbation risk (≤1 moderate exacerbation/year, no hospitalizations):

• Continue LAMA/LABA dual therapy 1
• Do NOT add ICS unless concomitant asthma is present

High exacerbation risk (≥2 moderate or ≥1 severe exacerbation/year):

• Triple therapy with LAMA/LABA/ICS is recommended 1
• Preferably use single-inhaler triple therapy (SITT) rather than multiple inhalers
• This reduces future exacerbations in symptomatic patients 1, 2

Step 4: Consider Add-On Therapies for Persistent Exacerbations

For patients on triple therapy who continue to exacerbate:

Prophylactic macrolide (azithromycin):

• 250 mg daily or 500 mg three times weekly 2
• Reduces exacerbations in former smokers
• Caution: Monitor for bacterial resistance and hearing impairment 2

PDE-4 inhibitor (roflumilast):

• For chronic bronchitis phenotype with severe-to-very severe COPD and exacerbation history 2
• Caution: Avoid in underweight patients; common side effects include diarrhea, nausea, weight loss 2

Mucolytic agents (N-acetylcysteine, carbocysteine):

• May reduce exacerbations in patients NOT on ICS 2
• Modest health status improvement 2

Critical Pitfalls to Avoid

1. Never use ICS monotherapy in stable COPD with low exacerbation risk 1 - this is explicitly recommended against

2. Avoid LAMA/LABA step-down in patients with CAT ≥10 or FEV₁ <80% once on triple therapy 1 - weak recommendation to continue triple therapy

3. Do not use ICS/LABA instead of LAMA/LABA as initial dual therapy unless concomitant asthma is present 1 - higher pneumonia risk with ICS

4. Avoid theophylline - narrow therapeutic index with serious adverse effects and uncertain efficacy 3

5. Do not use oral corticosteroids chronically - no benefit with high systemic complications 2

6. Roflumilast requires careful patient selection - avoid in depression and underweight patients 2

Special Considerations

Concomitant asthma: Use ICS/LABA combination therapy rather than LAMA/LABA 1

Blood eosinophil count: Emerging evidence suggests higher eosinophil counts predict better ICS response 4, though the 2023 Canadian guideline doesn't mandate this for decision-making

Inhaler technique: Poor technique is common in older patients using multiple devices 2 - use "teach-back" approach for education 2